

Description

Ready-to-use stabilized saGFP puroR RNA

Cap Modification: ExploCap™ | **Poly (A) Tail:** Yes

Concentration: 1.0 mg/mL

Buffer: 1 mM Sodium Citrate, pH 6.4

Full length mRNA: 9821 nt

Molecular weights: #MRNA119: 3167672 g/mol; #MRNA120: 3204872 g/mol.

OZB saGFP RNA has been constructed based on replicons of positive-sense ((+)-RNA) viruses (Venezuelan equine encephalitis Virus (VEEV)), where the coding sequence of the viral structural proteins is replaced with that of a gene of interest (GOI, here GFP), while retaining the coding sequences of non-structural proteins (NSPs), including the viral RNA-dependent RNA polymerase. Please note that OZB saRNAs encode also for Puromycin Resistance Cassette, which does not alter the expression of the GOI but can be used for cell selection (Fig1).

ExploCap SaGFP RNAs have been designed to produce high expression level of GFP protein with enhanced length of duration (see results). OZB RNAs are produced by *in vitro* transcription and are co-transcriptionally capped using trinucleotides ExploCap analog and contain a poly(A) tail at the 3' end. Sequences have been optimized to yield improved stability and performance. #MRNA119 does not bear any additional nucleotide modifications while #MRNA120 is modified with 5-methyl-Cytidine (m5C) (100% replacement of Cytidine).

Fig1. Structure of OZB saRNAs #MRN119 (unmodified nucleotides) and #MRN120 (m5C).



Applications

Self-amplifying RNAs (saRNAs) also called "Replicons" are the next generation of RNA vaccines. Their advantage over conventional mRNA vaccine platforms relies on the viral replication machinery, which amplifies the mRNA of the encoded gene of interest within target cells. In recent years, saRNA vaccines have been clinically tested with the hope of reducing the vaccination dose compared to the conventional mRNA approach. Replicons induce potent humoral and cellular responses with few adverse effects upon a minimal, single-dose immunization. Delivery of replicons is achieved with virus-like replicon particles (VRPs), or in nonviral vehicles such as liposomes or **lipid nanoparticles (LNPs)**.

General considerations on OZB's RNA

ExploCap saRNA GFP resemble fully matured mRNAs with 5' cap structure and 3' polyA tail, therefore ready to be translated by the ribosome.

mRNA transfection provides several advantages over plasmid DNA (pDNA) delivery. It does not require nuclear uptake for being expressed since translation of mRNA occurs directly into cytoplasm. Indeed, nuclear delivery (transport through nuclear membrane) is one of the principal barriers for transfecting slow or non-dividing cells and consequently, mRNA transfection is particularly attractive for such purpose. This approach presents also the advantage of being non-integrative which is particularly appealing for stem cells, regenerative medicine or vaccine fields. Contrary to pDNA, mRNA may not lead to genetic insertion causing mutations. Moreover, the protein expression from the mRNA is promoter-independent and faster than with DNA.

For saRNA transfection reagent, please contact us. ExploCap saRNA GFP can also be encapsulated into LNPs at OZ Biosciences with our proprietary ionizable lipids upon custom request.

Quality Controls

Items	Specification	Standard QC	Superior Grade QC*
Integrity	Agarose gel mobility and HPLC	✓	✓
Concentration	1mg/ml +/- 5%	✓	✓
A260/280	>1.8 for Unmodified mRNAs >1.7 for chemically modified mRNAs	✓	✓
Sterility	Absence of bacterial growth at 37°C	✓	✓
Functionality**	Test for protein expression	✓	✓
Endotoxin	<0.5 EU/mL		✓
dsRNA	<0.5%		✓

* Our catalogue mRNAs undergo the standard QC. Superior Grade QC can be performed as an additional prestation.

** For reporter mRNAs and Spike SARS-Cov2 related mRNAs only for catalog mRNAs. Can be included in superior Grade QC

Certificate of analysis on demand.

Use, handling and storage

For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes.

Long term storage (months): -80°C.

Short term storage (few days): -20°

We recommend to aliquot the saRNA solution for a better storage. Follow good laboratory practices for mRNA handling (work on ice, avoid freeze/thaw cycles, do not vortex, use RNase free water and barrier tips, ...)

Kit contents

ExploCap saRNA GFP-20: 20 µg of saRNA.

ExploCAP saRNA GFP-100: 100 µg of saRNA.

ExploCAP saRNA GFP-1000: 1 mg of saRNA.

Related Products

Custom mRNAs are also available now!

Bibliography

Jose J. *et al.*, *Future Microbiol.*, 2009. DOI:10.2217/fmb.09.59.

Spuul P., *et al.*, *J Virol.*, 2011. DOI:10.1128/JVI.00085-11.

Comes JDG., *et al.*, *Trends Biotechnol.*, 2023. DOI:10.1016/j.tibtech.2023.05.007.

Azizi H., *et al.*, *NAR Mol Med.*, 2024. DOI:doi.org/10.1093/namme/ugae004

Purchaser Notification | Conditions of Sale

ExploCap™ technology is licensed to OZ Biosciences by ExploRNA Therapeutics and is protected under patent WO2021162566. ExploCap is the intellectual property of ExploRNA Therapeutics. All mRNA products incorporating ExploCap are supplied for Research Use Only (RUO) and are not intended for diagnostic, therapeutic, or clinical use.

This product is sold in accordance with our general conditions of sale that you can find on our website: <https://ozbiosciences.com/content/3-terms-and-conditions>.